Novo Nordisk just lost a $10 billion bet on inflammation — and Wall Street didn't wait to find out why.
Shares crashed as much as 10% on Friday after the company's late-stage heart drug flopped in a major clinical trial.
The drug looked perfect on paper.
Right up until the results came in.
A once-monthly injection.
Designed to block IL-6 — a protein that fuels inflammation in your arteries.
The trial was called ZEUS.
Over 6,300 patients enrolled — all with heart disease, kidney disease, and high inflammation markers.
The question: could quieting inflammation stop heart attacks and strokes before they happen.
The drug did what it was supposed to do.
Inflammation markers dropped exactly as predicted.
But here's the gut punch:
The biology worked.
The biology just didn't matter.
This is the nightmare every drugmaker fears — hitting your lab target and still striking out where it counts.
Investors didn't wait for the fine print.
Copenhagen-listed shares tumbled nearly 10%.
US-listed shares slid over 8% in premarket trading.
Novo says its 2026 profit outlook stays intact.
But there's a catch — a non-cash impairment charge is coming in Q3.
Translation: the company is formally writing down a bet that didn't pay off.
Novo Nordisk built its empire on Ozempic and Wegovy.
Its diabetes and obesity franchise turned it into Europe's most valuable company.
But the race to diversify beyond weight-loss drugs — into cardiovascular disease — just took a hit.
Two more ziltivekimab trials, in heart failure and post-heart-attack patients, are still running.
Results land sometime in 2027.
So the story isn't over.
But today, the market delivered its verdict fast — and it wasn't kind.
That's all for now!
